We have launched our mobile app, get it now. Call : 9354229384, 9354252518, 9999830584.  

Current Affairs

New drug prevents progression of Osteoarthritis

Date: 02 January 2020 Tags: Miscellaneous

Issue

Researchers have found that “MIV-711”, a novel selective cathepsin K inhibitor can reduce disease progression in osteoarthritis.

 

Background

Osteoarthritis of the knee is a painful, disabling condition affecting more than 14 million people in the US and hundreds of millions worldwide.

 

Details

  • The pain of knee osteoarthritis arises from a series of pathologic processes involving articular cartilage, subchondral bone, synovium, meniscus, and other joint structures, ultimately leading to joint failure and pain-related functional limitations.

  • A team of researchers sought to test the hypothesis that cathepsin K inhibitor could alleviate osteoarthritis symptoms by reducing degeneration of bone and cartilage.

  • In the study, 244 patients with primary knee osteoarthritis were randomly assigned to receive either 100 or 200 mg daily of MIV-711 or matched placebo for 26 weeks to evaluate the efficacy, safety, and tolerability of MIV-711.

  • The primary endpoint of the study was change in pain score, but changes in disease progression were also assessed using quantitative MRI outcomes.

  • The researchers found that compared with placebo, MIV-711 was associated with less bone remodelling, less cartilage volume loss, and lower levels of bone resorption and collagen loss. However, it showed no beneficial effects on osteoarthritic knee pain.

  • Further evaluation was needed to confirm the structural benefits of MIV-711 and to determine whether these translate to more tangible benefits on disease symptoms.